Novartis (NVS) said Monday the European Commission approved Rhapsido for adults with chronic spontaneous urticaria who inadequately respond to traditional antihistamines.
Clinical trials demonstrated symptom improvements by the first week with a favorable safety record and no liver issues, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments